We came across a bullish thesis on Merus N.V. on BiotechBonanza’s Substack by AnotherBio. In this article, we will summarize the bulls’ thesis on MRUS. Merus N.V.’s share was trading at $95.99 as of December 2nd.
Photo by National Cancer Institute on Unsplash
Genmab’s acquisition of Merus for $97 per share has been well received by the market, with Genmab’s stock reacting positively despite the deal’s significant size. The transaction reflects continued consolidation in the...
